Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Richard Lafayette, MD, FACP
Ankana Daga, MD
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Joseph Rossano, MD
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
Ahmad Masri, MD, MS
Anjali Owens, MD
Cracking the Code of Obstruction: Unmet Needs in oHCM
Michael Nassif, MD, MSc
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Jonathan Barratt, MD, PhD
Individualized Management of Hyperkalemia: The Role of Potassium Binders in Patients With Cardiorenal Disease
Ellie Kelepouris, MD, FACP, FAHA
Kappa-Opioid Settings: Real-World Evidence Insights
Lucio Manenti, MD, PhD
Emilio Sanchez, MD, PhD
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
James Burton, DM, FRCP
Leonie Kraft, MD
The Patient-Clinician Connection in Managing CKD-aP
Elevating CKD-aP Care: New Frontier
CKD-aP or Something Else? Decoding the Diagnosis
CKD-aP Treatment Tool Kit
Optimizing IgAN Care: Sparsentan’s Role Amid the Latest KDIGO Guideline Updates
Jürgen Floege, MD